Hematologic Variables and Parameters of Iron Metabolism in Both Groups 14 Days Preoperatively, Immediately Before Surgery, and 7 Days Postoperatively
| Variable . | Treatment Group . | 14 Days Preoperatively . | Day of Surgery Preoperatively . | 7 Days Postoperatively . |
|---|---|---|---|---|
| Hb (g/dL) | Epoetin beta (n = 36) | 14.31 ± 0.98 | 15.84 ± 1.113-150 | 13.41 ± 2.113-151 |
| Placebo (n = 36) | 13.78 ± 1.03 | 13.97 ± 1.06 | 11.99 ± 1.80 | |
| Difference (95% CI)3-152 | 1.50 (1.10-1.90) | 1.01 (0.21-1.80) | ||
| Hct (L/L) | Epoetin beta (n = 36) | 0.42 ± 0.03 | 0.48 ± 0.033-150 | 0.41 ± 0.06ρ |
| Placebo (n = 36) | 0.41 ± 0.03 | 0.41 ± 0.03 | 0.36 ± 0.04 | |
| Difference (95% CI)3-152 | 0.06 (0.05-0.07) | 0.04 (0.02-0.07) | ||
| Reticulocytes (%) | Epoetin beta (n = 36) | 1.30 ± 0.40 | 4.90 ± 1.493-150 | 2.09 ± 1.21 |
| Placebo (n = 36) | 1.33 ± 0.37 | 1.51 ± 0.52 | 2.42 ± 0.98 | |
| Difference (95% CI)3-152 | 3.41 (2.89-3.92) | −3.2 (−8.4-1.9) | ||
| Ferritin (ng/mL) | Epoetin beta (n = 36) | 145 ± 126 | 78 ± 703-150 | 319 ± 267 (n = 32) |
| Placebo (n = 36) | 118 ± 77 | 148 ± 83 | 309 ± 252 (n = 33) | |
| Difference (95% CI)3-152 | −86 (−106-−68) | −8 (−132-115) | ||
| Iron (μmol/L) | Epoetin beta (n = 36) | 13.4 ± 5.3 | 8.2 ± 6.33-150 | 7.0 ± 5.0 (n = 35) |
| Placebo (n = 36) | 12.8 ± 5.9 | 17.5 ± 5.7 | 7.0 ± 3.8 (n = 33) | |
| Difference (95% CI)3-152 | −9.6 (−12.2-−7.0) | −0.2 (−2.3-1.9) | ||
| Transferrin saturation (%) | Epoetin beta (n = 36) | 19.3 ± 7.8 | 12.7 ± 8.33-150 | 13.4 ± 13.1 (n = 35) |
| Placebo (n = 36) | 18.5 ± 8.9 | 28.4 ± 10.0 | 12.8 ± 10.4 (n = 31) | |
| Difference (95% CI)3-152 | −16.0 (−20.1-−12.0) | 0.3 (−5.5-6.0) |
| Variable . | Treatment Group . | 14 Days Preoperatively . | Day of Surgery Preoperatively . | 7 Days Postoperatively . |
|---|---|---|---|---|
| Hb (g/dL) | Epoetin beta (n = 36) | 14.31 ± 0.98 | 15.84 ± 1.113-150 | 13.41 ± 2.113-151 |
| Placebo (n = 36) | 13.78 ± 1.03 | 13.97 ± 1.06 | 11.99 ± 1.80 | |
| Difference (95% CI)3-152 | 1.50 (1.10-1.90) | 1.01 (0.21-1.80) | ||
| Hct (L/L) | Epoetin beta (n = 36) | 0.42 ± 0.03 | 0.48 ± 0.033-150 | 0.41 ± 0.06ρ |
| Placebo (n = 36) | 0.41 ± 0.03 | 0.41 ± 0.03 | 0.36 ± 0.04 | |
| Difference (95% CI)3-152 | 0.06 (0.05-0.07) | 0.04 (0.02-0.07) | ||
| Reticulocytes (%) | Epoetin beta (n = 36) | 1.30 ± 0.40 | 4.90 ± 1.493-150 | 2.09 ± 1.21 |
| Placebo (n = 36) | 1.33 ± 0.37 | 1.51 ± 0.52 | 2.42 ± 0.98 | |
| Difference (95% CI)3-152 | 3.41 (2.89-3.92) | −3.2 (−8.4-1.9) | ||
| Ferritin (ng/mL) | Epoetin beta (n = 36) | 145 ± 126 | 78 ± 703-150 | 319 ± 267 (n = 32) |
| Placebo (n = 36) | 118 ± 77 | 148 ± 83 | 309 ± 252 (n = 33) | |
| Difference (95% CI)3-152 | −86 (−106-−68) | −8 (−132-115) | ||
| Iron (μmol/L) | Epoetin beta (n = 36) | 13.4 ± 5.3 | 8.2 ± 6.33-150 | 7.0 ± 5.0 (n = 35) |
| Placebo (n = 36) | 12.8 ± 5.9 | 17.5 ± 5.7 | 7.0 ± 3.8 (n = 33) | |
| Difference (95% CI)3-152 | −9.6 (−12.2-−7.0) | −0.2 (−2.3-1.9) | ||
| Transferrin saturation (%) | Epoetin beta (n = 36) | 19.3 ± 7.8 | 12.7 ± 8.33-150 | 13.4 ± 13.1 (n = 35) |
| Placebo (n = 36) | 18.5 ± 8.9 | 28.4 ± 10.0 | 12.8 ± 10.4 (n = 31) | |
| Difference (95% CI)3-152 | −16.0 (−20.1-−12.0) | 0.3 (−5.5-6.0) |